期刊文献+

流式细胞术检测CIK的免疫表型和体外杀伤活性 被引量:6

Measurement of immunophenotype and cytotoxicity of CIK against tumor cells in vitro by FCM
下载PDF
导出
摘要 目的:探讨细胞因子诱导的杀伤细胞(cytokine-induced killer,CIK)的免疫表型和体外杀伤活性。方法:从健康人外周血分离淋巴细胞,经过IFNγ、CD3McAb、IL-2诱导并培养,获得大量的CIK。采用流式细胞术检测CIK的表型;以CFSE标记靶细胞来区分效应细胞,再以PI染色,用FACS检测靶细胞的死亡率。结果:CIK于第22天达到增殖高峰,并高度表达CD3、CD11a、CD54和HLA-DR;中度表达CD3/CD56、CD25、CD28、CD69和FasL;CD16表达不增加。CIK对肿瘤细胞K562、HL-60、Hela、SMMC7721和A375均表现出杀伤活性,其中对K562、HL-60、Hela 3种细胞的杀伤作用较强;而对SMMC7721、A375的作用不明显。结论:细胞因子IFNγ、CD3McAb和IL-2体外诱导的单个核细胞具有强大的增殖力和杀伤活性。 Objective To investigate the immunophenotype and the eytotoxieity of eytokine-indueed killer (CIK) against tumor eells in vitro. Methods Lymphoeytes eells were isolated freshly from peripheral blood of healthy donors by Fieoll-Hypaque density eentrifugation, and the eells obstained were indueed by IFNγ, IL-2 and CD3MeAb. Phenotypes and eytotoxieity of CIK were analysed by FACS. Target eells were differentiated from effeet eells by CFSE dying. The mortality of Target eells were determined by FACS. Results The maximum proliferation of CIK reaehed at the 22nd day. The phenotypes of CD3, CD11a, CD54, HLA-DR were expressed highly; CD25, CD28, CD69, FasL were expressed moderately on CIK. The expression of CD16 was not increased. CIK possessed the eytotoxieity against tumor eells of K562, HL-60, Hela, SMMC7721 and A375. Conclusion IFNT, CD3MeAb, IL-2 ean induee peripheral lymphoeytes to produee CIK whieh own strongly proliferation and exert highly effieient eytotoxie effects on tumor cells.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2006年第4期639-642,共4页 Journal of Jilin University:Medicine Edition
基金 吉林省科技厅重点科研项目资助课题(20050402-3) 吉林省科技厅国际合作项目资助课题(20040707-2) 高等学校博士学科点专项科研基金资助课题(20020183017)
关键词 细胞因子诱导的杀伤细胞 免疫表型 杀伤活性 流式细胞术 eytokine-indueed killer immunophenotype eytotoxieity flow cytometry
  • 相关文献

参考文献11

  • 1Schmidt-Wolf GD,Negrin RS,Schmidt-Wolf IG.Activated T cells and cytokine-induced CD3^+CD56^+ killer cells[J].Ann Hematol,1997,74(2):51-56.
  • 2王晓祺,谭岩,段秀梅,刘玲丽,方艳秋,姜艳芳,许淑芬,刘力华.流式细胞术检测细胞毒方法的建立[J].中国免疫学杂志,2004,20(10):704-707. 被引量:14
  • 3Schmidt-Wolf IGH,Negrin RS,Kiem H,et al.Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer with potent antitumor cell activity[J].J Exp Med,1991,174(1):139-149.
  • 4Hongeng S,Petvises S,Worapongpaiboon S,et al.Generation of CD3^+CD56^+ cytokine-induced killer and their in vitro cytotoxicity against pediatric cancer cells[J].Int J Hematol,2003,77(2):175-179.
  • 5Ocha AC,Gromo G,Alter BS,et al.Long-term growth of lymphokine activated killer(LAK)cells:role of anti CD3,β-IL-1,αand γ-IFN[J].J Immunol,1987,138(8):2728-2733.
  • 6Zoll B,Lefterova P,Ebert O,et al.Modulation of cell surface markers on NK-like T lymphocytes by using IL-2,IL-7 or IL-12 in vitro stimulation[J].Cytokine,2000,12(9):1385-1390.
  • 7Mehta BA,Schmidt-Wolf IG,Negrin RS,et al.Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine -induced CD3^+CD56^+ killer cells[J].Blood,1995,86(9):3493-3499.
  • 8Verneris MR,Kornacker M,Mailander V,et al.Resistance of ex vivo expanded CD3^+CD56^+ T cells to Fas-mediated apoptosis[J].Cancer Immunol Immunother,2000,49(6):335-345.
  • 9Hualu P,Negrin PS.A novel population of expanded human CD3^+CD56^+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency[J].J Immunol,1994,153(4):1687-1696.
  • 10Hoyle C,Bangs CD,Chang P,et al.Expansion of Philadelphia chromosome-negative CD3^+CD56^+ cytotoxic cells from chronic myeloid leukemia patients:in vitro and in vivo efficacy in severe combined immunodeficiency disease mice[J].Blood,1998,92(9):3318-3327.

二级参考文献31

  • 1Finke S, Trojaneck B, Lefterova Pet al. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD66+ immunologic effector cens by receptor-mediated transfection with the interleukin-7 gene. Gene Ther, 1998,5(1) : 31.
  • 2Schmidt-Wolf IG, Lefterova P, Johnston Vet al. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol, 1994,87(3) : 453.
  • 3Schmidt-Wolf IG, Negrin RS, Kiem FIP et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med, 1991, 174(1): 139.
  • 4Vemeris MR, Komacker M, Mailander V et al. Resistance of ex vivo expanded CD3+ CD66+ T cells to Fas-mediated apoptosis. Cancer Immunol Immunother, 2000,49(6): 335.
  • 5Umehara H, Inoue H, Huang Jet al. Role for adapter proteins in costimulatory signals of CD2 and IL-2 on NK cell activation. Mol Immunol,2002, 38(8): 587.
  • 6Zoll B, Lefterova P, Ebert O et al. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 invitro stimulation. Cytokine, 2000, 12(9): 1 385.
  • 7Mehta BA, Schmidt-Wolf IG, Weissman IL et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokineinduced CD3+ CD66+ killer cells. Blood, 1995,86(9):3 493.
  • 8Takasaki S, Hayashida K, Morita C et al. CD66 directly interacts in the process of NCAM-positive target cell-killing by NK cells. Cell Biol Int,2000, 24(2): 101.
  • 9Ortaldo JR, Winkler-Pickett RT, Yagita H et al. Comparative studies of CD3- and CD3+ CD66+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol, 1991, 136(2): 486.
  • 10Hoyle C, Bangs CD, Chang Pet al. Expansion of Philadelphia chromosome-negative CI)3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood, 1998,92(9): 3 318.

共引文献22

同被引文献56

  • 1朱建平,徐鸣,汝美华.CIK细胞临床应用技术规范探讨[J].中国医药生物技术,2007,2(2):148-150. 被引量:12
  • 2蒋敬庭,吴昌平,邓海峰,陆明洋,李敏,王赫,吴骏.细胞因子诱导的杀伤细胞与肿瘤浸润淋巴细胞体外细胞毒活性比较[J].检验医学,2005,20(4):322-324. 被引量:18
  • 3吴昌平,蒋敬庭,邓海峰,陆明洋,李敏,王赫,吴骏,张红宇,季枚,赵伟庆.CIK细胞体外培养的免疫表型[J].江苏医药,2005,31(9):644-645. 被引量:20
  • 4王建华.肝癌综合介入治疗的现状[J].中华肝脏病杂志,2005,13(10):721-723. 被引量:80
  • 5何跃,谢新波,秦文珍,林学颜,湛海伦,高新.特异性抗原致敏的DC-CIK细胞对肿瘤细胞的杀伤效应[J].中国生物制品学杂志,2007,20(5):343-345. 被引量:8
  • 6Lordick F, Luber B, Eorenzen S, et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer, a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer, 2010, 102 (3): 500-505.
  • 7Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist, 2002, 7 Suppl 4: 2-8.
  • 8Matin V, Dander E, Biagi E, et al. Characterization of in vitro migratory properties of anti-CD19 chimeric receptorredirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol, 2006, 34 (9): 1219-1229.
  • 9Ma H, Zhang Y, Wang Q, et al. Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell im,nunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation [ J]. Cancer Biol Ther, 2010,9(11) :903.
  • 10Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside [ J]. J Biomed Biotechnol, 2010, 2010:435745. Epub 2010 Mar 30.

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部